BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
BMS-275291 may stop the growth of prostate cancer by stopping blood flow to the tumor and by
blocking the enzymes necessary for tumor cell growth. Randomized phase II trial to study the
effectiveness of BMS-275291 in treating patients who have prostate cancer that has not
responded to hormone therapy